Navigation Links
Micromet's Blinatumomab Induces Durable Remissions in Patients with Relapsed Non-Hodgkin's Lymphoma
Date:6/14/2010

BETHESDA, Md., June 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma (NHL).  A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing.  Blinatumomab is the first in a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

The findings were presented on June 12, 2010 in an oral presentation (abstract # 0559) at the 15th Annual Congress of the European Hematology Association (EHA) in Barcelona, Spain.

"Blinatumomab continues to demonstrate a long duration of response in heavily pre-treated non-Hodgkin's lymphoma patients," said Professor Ralph Bargou, Division of Hematology and Oncology, Department of Internal Medicine II, Wuerzburg University Hospital, and the study's principal investigator. "Results of the expanded Phase 1 experience suggest that blinatumomab has the potential to alter the clinical course of disease in patients with a variety of NHL sub-types."

Phase 1 Study Design

This multi-center Phase 1 study evaluates the safety and tolerability of blinatumomab in adult patients with relapsed non-Hodgkin's lymphoma (NHL).  The key objectives of the study are to assess safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-lymphoma activity. &#
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
2. Final Data from Phase 2 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
3. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
4. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
5. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
6. Clinical Data Published in Science Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
7. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
8. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
9. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
10. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
11. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015   NineSigma the leading innovation partner to ... estimated overall revenue growth and anticipates the creation of over ... Open Innovation Incentive (OII). In 2013, the ... of over $2 million to accelerate adoption of open innovation ... and $1 Billion in revenues. To date over 45 middle ...
(Date:8/27/2015)... , Aug. 27, 2015  Generex Biotechnology Corporation ... of a white paper on the status of Generex ... white paper was presented to the August 19, 2015 ... James H. Anderson, Jr. , MD, the Company,s Chief ... on the Generex website. The white paper ...
(Date:8/27/2015)... Calif. , Aug. 27, 2015  Mytrus, a technology and ... software platform for electronic informed consent has received approval ... Health Service (NHS). It is the first time e-Consent ... England . Mytrus was ... use in a clinical trial by the U.S. Food ...
Breaking Medicine Technology:State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 2State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 3Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7
... Corporation today,announced that it is seeking 510(k) authorization ... use of its FluDetect(R) Avian Influenza Virus,rapid test ... into the,human point-of-care diagnostic marketplace. While it is ... to the human field, it is,actively seeking an ...
... In Children,s DNA, a Hint of a Mutation,s Ancestral ... researchers,seeking to replicate another group,s discovery of an important ... a particular,variant in DNA that may be more helpful ... populations worldwide. The finding suggests that,the gene variant, identified ...
Cached Medicine Technology:Synbiotics Corporation Announces Human Submission for FluDetect(R) 2Gene Hunters Fine-Tune Marker for Common Obesity Gene 2Gene Hunters Fine-Tune Marker for Common Obesity Gene 3
(Date:8/28/2015)... St. Louis, MO (PRWEB) , ... August 28, ... ... defendants in testosterone lawsuits now consolidated as MDL 2545, Testosterone Replacement ... establishment of a cap on the number of custodial files the PSC may ...
(Date:8/28/2015)... ... 28, 2015 , ... A complimentary webinar offered by healthcare consulting and accounting ... proposal to mandate bundled payments through the Comprehensive Care for Joint Replacement ... Comprehensive Care for Joint Replacement,” takes place at 12 noon EDT on Wednesday, September ...
(Date:8/28/2015)... ... ... Super-Sod launched their new website this summer. The new user-friendly site has ... web design. Website users will now have an improved browsing experience on their phones, ... for the monthly turf-tips email, and find a local Super-Sod store all from the ...
(Date:8/28/2015)... ... 2015 , ... Where can successful, well educated, or attractive ... up to help quality singles find dating partners or ideal matches. , ... well educated, or attractive. , It updates profiles under the category of " ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... through health promotion and disease prevention, improving a patient’s quality of life through ... the community, including heart disease, cancer, diabetes, HIV/AIDS, STDs, and others. A Women’s, ...
Breaking Medicine News(10 mins):Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4Health News:PYA Offers Complimentary CCJR Webina — Game On 2Health News:PYA Offers Complimentary CCJR Webina — Game On 3Health News:MillionaireMatchmakerOnline.net Collects and Updates Newest Millionaire and Quality Single Profiles on the Page of Millionaire Matchmaker Online Canada. 2Health News:MillionaireMatchmakerOnline.net Collects and Updates Newest Millionaire and Quality Single Profiles on the Page of Millionaire Matchmaker Online Canada. 3Health News:Health Clinic Opening and Public Art Unveiling 2
... non-cancerous breast disease, study finds , MONDAY, April 12 (HealthDay ... the chances that they will develop non-cancerous breast disease in ... Research published online April 12 in the journal Pediatrics ... their teen years -- daily or nearly every day -- ...
... to support the fact that smoking in cars is 23 ... analysis article in CMAJ ( Canadian Medical Association ... article, by Australian researchers, describes how a local media report ... times more toxic in a vehicle than in a home"" ...
... of air pollutants, especially nitrogen dioxide, has been associated ... in vitro fertilization, according to a team of fertility ... the first pregnancy attempt of 7,403 women undergoing IVF ... Pa.; Shady Grove Fertility, Rockville, Md.; and Columbia University ...
... Girls and young women who drink alcohol increase their ... by researchers at Washington University School of Medicine in ... the risk for developing breast cancer. "Our study ... increased with the amount of alcohol consumed in this ...
... COLUMBUS, Ohio Most women scheduled for gynecologic surgery to ... they were not worried about the effects of the procedure ... of women planning to be sterilized did express concern in ... the operation even though that surgery does not affect ...
... ... helps women improve body image and boost confidence in time for summer with laser hair ... ... many women, spring ushers in the season of renewed commitment to diet and exercise in ...
Cached Medicine News:Health News:Teen Drinking May Boost Breast Problems Later 2Health News:Teen Drinking May Boost Breast Problems Later 3Health News:Second-hand smoke toxicity in cars: Myth into fact 2Health News:Exposure to nitrogen dioxide lowers in vitro fertilization success 2Health News:Adolescent drinking adds to risk of breast disease, breast cancer 2Health News:Most women facing gynecologic surgery don't worry about its effects on sex 2Health News:Most women facing gynecologic surgery don't worry about its effects on sex 3Health News:Most women facing gynecologic surgery don't worry about its effects on sex 4Health News:Epione Helps Women Get Ready for Bikini Season without Hitting the Gym 2Health News:Epione Helps Women Get Ready for Bikini Season without Hitting the Gym 3
Open wire loops decrease the chance of interfering with instruments, Designed to retract the eyelid during ophthalmic microsurgery or minor office procedures...
Blunt, round tip facilitates easier separation of the nucleus. 45 6.0mm from tip, Blunt, Angled, 6.0mm from tip, 1.5mm from end...
Unique 2 in 1 design allows simultaneous absorption of excess fluid & protection of flap & hinge, Lint-free PVAmaterial....
Smaller diameter wire probes & olive shape tips provide easier insertion through the lacrimal sac, 35cm (14 in) long, ID- .30mm (.012in); OD- .64mm (.025 in). S.S. Probes: .40mm x 11cm (27 G x 4 1/4...
Medicine Products: